Neurocrine jumps 6.6% after hours as Q3 EPS of $3.29 tops Investing.com · · AI-summarised by FinFlash
Neurocrine Biosciences posted third-quarter adjusted earnings of $3.29 a share against a So What?
The beat and raise favour mid-cap biotech names with commercial products. Watch whether a $20 million INGREZZA order-timing benefit reversing in Q4 tempers the move.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.
Investing.com · · AI-summarised by FinFlash
Neurocrine Biosciences posted third-quarter adjusted earnings of $3.29 a share against a The beat and raise favour mid-cap biotech names with commercial products. Watch whether a $20 million INGREZZA order-timing benefit reversing in Q4 tempers the move. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context